Trial site

Hope Clin Res & Wellness

Conyers, Georgia 30094, United StatesNot linked to an institution yet

12running trials
6closed trials

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions: Obesity13 trials
Type 2 diabetes6 trials
Chronic kidney disease1 trial
Heart failure1 trial
High blood pressure1 trial
Osteoarthritis1 trial
Type 1 diabetes1 trial
Phase: Phase 316 trials
Phase 11 trial
Phase 21 trial
Status: Completed5 trials
Recruiting5 trials
Not yet recruiting4 trials
Active, not recruiting3 trials
Withdrawn1 trial
Lead sponsor: Novo Nordisk A/S18 trials

Running trials

Not yet recruiting
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
NCT07720271· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
NCT07745504· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587· Phase 1· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07481630· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
NCT07339423· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Active, not recruiting
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Obesity8 recruiting
Heart failure1 recruiting
High blood pressure1 recruiting
Osteoarthritis1 recruiting
Type 2 diabetes1 recruiting

Closed trials

Withdrawn
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
NCT07357740· Phase 2· Novo Nordisk A/S· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06221969· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
NCT05649137· Phase 3· Novo Nordisk A/S· Source
Completed
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835· Phase 3· Novo Nordisk A/S· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error